They also concluded that to minimize the risk of therapy failure, a pretreatment genetic testing for HLA-DQA1*05 might be helpful in deciding whether to use anti-TNF, or combination therapy in IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.